A RANDOMISED NON-COMPARATIVE OPEN LABEL PHASE II TRIAL OF ATEZOLIZUMAB PLUS BEVACIZUMAB, WITH CARBOPLATIN-PACLITAXEL OR PEMETREXED, IN EGFR-MUTANT NON-SMALL CELL LUNG CARCINOMA WITH ACQUIRED RESISTANCE.
2019-001687-30CARCINOMA DE PULMONFundación Jiménez DíazInvestigador: DOMINE GOMEZ MANUEL
